News

Last week Andrew D’Silva of B Riley FBR launched research coverage on EDAP TMS with a buy-rating and price target at $5.50. His report highlighted Focal One® HIFU as an industry-leading focal ablation technology and an underappreciated opportunity that fills the significant void in the treatment paradigm for prostate cancer between active surveillance and radical surgery/radiation therapy. He shares our view that, while we anticipate COVID-19 to impact our operations, EDAP’s activities are expected to rebound on the other side of this worldwide crisis and is poised to show growth in a normalized environment, while expanding into numerous other clinical indications.